 SYDNEY, AUSTRALIA, Sept. 29, 2021 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a 2,126,617 A3,430,952 research and development RD tax incentive payment in cash from the French Government under its Crédit dImpôt Recherche scheme CIR. 